Endoscopy 2010; 42(4): 272-278
DOI: 10.1055/s-0029-1243883
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Radiofrequency ablation of Barrett’s esophagus: outcomes of 429 patients from a multicenter community practice registry

W.  D.  Lyday1 , F.  S.  Corbett2 , D.  A.  Kuperman2 , I.  Kalvaria2 , P.  G.  Mavrelis3 , A.  B.  Shughoury3 , R.  E.  Pruitt4
  • 1The Center for GI Health, Cancer Prevention, Management and Nutritional Therapy, A Division of Atlanta Gastroenterology Associates, LLC, Atlanta, Atlanta, Georgia, USA
  • 2Sarasota Memorial Hospital, Sarasota, Florida, USA
  • 3St Mary’s Medical Center, Hobart, Indiana, USA
  • 4Maria Nathanson Center of Excellence at St Thomas Hospital, Nashville, Tennessee, USA
Further Information

Publication History

submitted 12 June 2009

accepted after revision 16 December 2009

Publication Date:
09 February 2010 (online)

Preview

Background and study aims: The use of radiofrequency ablation (RFA) for complete eradication of Barrett’s esophagus has shown promise in trials conducted at predominantly tertiary academic centers; however less is known regarding outcomes in the community. We evaluated the safety and efficacy of RFA for Barrett’s esophagus delivered in a community practice setting.

Patients and methods: This was a multicenter registry conducted in community-based gastroenterology practices. Patients had confirmed intestinal metaplasia with or without dysplasia on biopsy of a Barrett’s esophagus. Intervention was step-wise RFA with follow-up esophageal biopsies. Endpoints were histology-based; complete response was defined as all biopsies at most recent endoscopy negative for intestinal metaplasia (CR-IM) or dysplasia (CR-D). Three cohorts were reported: 1) safety cohort, all patients; 2) efficacy cohort A, patients with at least one biopsy session after initial treatment; 3) efficacy cohort B, patients with at least one biopsy session ≥ 1 year after initial treatment.

Results: The safety cohort included 429 patients (71 % men, median age 59 years, median Barrett’s segment 3.0 cm). There were no serious adverse events (bleeding, perforation, death), and a stricture occurred after 1.1 % of cases (2.1 % of patients). In efficacy cohort A (n = 338), CR-IM and CR-D were achieved in 72 % and 89 % of patients, respectively (median follow-up 9 months). In efficacy cohort B (n = 137), CR-IM and CR-D were achieved in 77 % and 100 % of patients, respectively (median follow-up 20 months).

Conclusions: In this multicenter registry conducted at four community-based practices, the observed safety and efficacy outcomes associated with RFA for Barrett’s esophagus are comparable to those previously reported in multicenter trials from predominantly tertiary academic centers.

References

R. E. PruittMD 

Maria Nathanson Center of Excellence
St Thomas Hospital

4220 Harding Pike
Suite 309 W
Nashville
TN 37205
USA

Fax: +1-615-292-4657

Email: scopeman1@msn.com